002390.KS
HANDOK Inc. [002390.KS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
002390.KS Stock Summary
Top 10 Correlated ETFs
002390.KS
Top 10 Correlated Stocks
002390.KS
In the News
002390.KS Financial details
Company Rating
Buy
Market Cap
178.51B
Income
-5.65B
Revenue
532.18B
Book val./share
26123.97
Cash/share
2694.41
Dividend
400
Dividend %
3.11%
Employees
911
Optionable
No
Shortable
Yes
Earnings
07 Feb 2024
P/E
-31.33
Forward P/E
-
PEG
1.15
P/S
0.33
P/B
0.49
P/C
4.75
P/FCF
7.67
Quick Ratio
0.85
Current Ratio
1.18
Debt / Equity
0.84
LT Debt / Equity
0.45
-
-
EPS (TTM)
-411.06
EPS next Y
-
EPS next Q
-
EPS this Y
224.64%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
5.63%
Revenue last 5Y
4.01%
Revenue Q/Q
-9.48%
EPS Q/Q
-49.55%
-
-
-
-
SMA20
5.16%
SMA50
-1.15%
SMA100
-7.23%
Inst Own
-
Inst Trans
-
ROA
-1%
ROE
-2%
ROC
0.07%
Gross Margin
33%
Oper. Margin
7%
Profit Margin
-1%
Payout
-
Shs Outstand
13.76M
Shs Float
7.8M
-
-
-
-
Target Price
-
52W Range
11480.0-18400.0
52W High
-30.38%
52W Low
+11.59%
RSI
52.35
Rel Volume
0.63
Avg Volume
19.98K
Volume
12.63K
Perf Week
-0.47%
Perf Month
9.96%
Perf Quarter
-11.96%
Perf Half Y
-16.22%
-
-
-
-
Beta
0.586
-
-
Volatility
81.67%, 420.21%
Prev Close
-1.23%
Price
12810
Change
-0.23%
002390.KS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 32.99K | 34.45K | 36.58K | 37.55K | 39.49K | |
| Net income per share | 590 | 2.54K | 1.96K | 239 | 775.88 | |
| Operating cash flow per share | 2.18K | 640.81 | 1.77K | 2.7K | 2.22K | |
| Free cash flow per share | 580.68 | -1.25K | 121.61 | -451.9 | -960.06 | |
| Cash per share | 2.59K | 2.22K | 2.45K | 2.57K | 2.89K | |
| Book value per share | 22.7K | 24.82K | 27.69K | 27.85K | 27.58K | |
| Tangible book value per share | 15.83K | 18.03K | 21.05K | 21.97K | 21.72K | |
| Share holders equity per share | 22.7K | 24.82K | 27.69K | 27.85K | 27.58K | |
| Interest debt per share | 12.13K | 16.16K | 17.49K | 19.16K | 22.26K | |
| Market cap | 436.72B | 310.98B | 458.51B | 314.32B | 232.02B | |
| Enterprise value | 562.64B | 508.3B | 668.8B | 542.27B | 493.46B | |
| P/E ratio | 54.66 | 8.9 | 17.01 | 95.4 | 21.72 | |
| Price to sales ratio | 0.98 | 0.66 | 0.91 | 0.61 | 0.43 | |
| POCF ratio | 14.83 | 35.35 | 18.84 | 8.44 | 7.6 | |
| PFCF ratio | 55.54 | -18.05 | 273.83 | -50.45 | -17.55 | |
| P/B Ratio | 1.42 | 0.91 | 1.2 | 0.82 | 0.61 | |
| PTB ratio | 1.42 | 0.91 | 1.2 | 0.82 | 0.61 | |
| EV to sales | 1.26 | 1.07 | 1.33 | 1.05 | 0.91 | |
| Enterprise value over EBITDA | 15.82 | 6.44 | 9.64 | 13.9 | 11.97 | |
| EV to operating cash flow | 19.1 | 57.77 | 27.48 | 14.57 | 16.17 | |
| EV to free cash flow | 71.55 | -29.51 | 399.42 | -87.05 | -37.33 | |
| Earnings yield | 0.02 | 0.11 | 0.06 | 0.01 | 0.05 | |
| Free cash flow yield | 0.02 | -0.06 | 0 | -0.02 | -0.06 | |
| Debt to equity | 0.52 | 0.63 | 0.61 | 0.67 | 0.79 | |
| Debt to assets | 0.24 | 0.29 | 0.29 | 0.31 | 0.34 | |
| Net debt to EBITDA | 3.54 | 2.5 | 3.03 | 5.84 | 6.34 | |
| Current ratio | 1.1 | 1.16 | 1.44 | 1.17 | 1.31 | |
| Interest coverage | 2.67 | 8.66 | 7.09 | 3.06 | 2.37 | |
| Income quality | 3.15 | 0.18 | 0.58 | 7.81 | 4.17 | |
| Dividend Yield | 0.01 | 0.02 | 0.01 | 0.01 | 0.02 | |
| Payout ratio | 0.41 | 0.18 | 0.14 | 1.25 | 0.45 | |
| Sales general and administrative to revenue | 0.05 | 0.05 | 0.04 | 0.04 | 0.04 | |
| Research and developement to revenue | 0.05 | 0.04 | 0.04 | 0.04 | 0.04 | |
| Intangibles to total assets | 0.15 | 0.13 | 0.11 | 0.1 | 0.09 | |
| Capex to operating cash flow | -0.73 | -2.96 | -0.93 | -1.17 | -1.43 | |
| Capex to revenue | -0.05 | -0.06 | -0.05 | -0.08 | -0.08 | |
| Capex to depreciation | -1.08 | -1.21 | -1.06 | -2.03 | -2.01 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 17.36K | 37.69K | 34.93K | 12.24K | 21.94K | |
| ROIC | 0.03 | 0.07 | 0.05 | 0.02 | 0.04 | |
| Return on tangible assets | 0.01 | 0.05 | 0.04 | 0 | 0.01 | |
| Graham Net | -10.16K | -13.78K | -14.81K | -16.37K | -17.2K | |
| Working capital | 26.32B | 41.72B | 100.53B | 47.74B | 83.24B | |
| Tangible asset value | 214.42B | 247.58B | 289.87B | 302.9B | 299.12B | |
| Net current asset value | -55.45B | -95.07B | -108.86B | -132.04B | -135.08B | |
| Invested capital | 0.52 | 0.63 | 0.61 | 0.67 | 0.79 | |
| Average receivables | 164.79B | 177.06B | 196.81B | 207.97B | 213.82B | |
| Average payables | 81.77B | 90.6B | 92.47B | 93.46B | 100.69B | |
| Average inventory | 72.59B | 85.85B | 89.22B | 83.92B | 88.28B | |
| Days sales outstanding | 139.42 | 141.59 | 152.3 | 145.11 | 148.92 | |
| Days payables outstanding | 114.3 | 107.84 | 102.61 | 96.62 | 107.22 | |
| Days of inventory on hand | 97.26 | 112.59 | 91.17 | 87.68 | 91.2 | |
| Receivables turnover | 2.62 | 2.58 | 2.4 | 2.52 | 2.45 | |
| Payables turnover | 3.19 | 3.38 | 3.56 | 3.78 | 3.4 | |
| Inventory turnover | 3.75 | 3.24 | 4 | 4.16 | 4 | |
| ROE | 0.03 | 0.1 | 0.07 | 0.01 | 0.03 | |
| Capex per share | -1.59K | -1.9K | -1.65K | -3.15K | -3.18K |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 10.79K | 9.87K | 9.33K | 10.21K | 9.24K | |
| Net income per share | 290.36 | 573.34 | -319.4 | -442 | -223 | |
| Operating cash flow per share | 376.88 | 903.45 | 2.78K | -676.69 | 953.14 | |
| Free cash flow per share | -91.76 | 42.25 | 2.3K | -1.26K | 586.4 | |
| Cash per share | 1.94K | 2.89K | 4K | 1.63K | 2.69K | |
| Book value per share | 27.24K | 27.56K | 26.96K | 26.37K | 26.12K | |
| Tangible book value per share | 21.58K | 21.71K | 21K | 20.46K | 20.23K | |
| Share holders equity per share | 27.24K | 27.56K | 26.96K | 26.37K | 26.12K | |
| Interest debt per share | 20.98K | 21.85K | 21.76K | 21.45K | 22.33K | |
| Market cap | 203.7B | 232.2B | 207.16B | 196.39B | 179.2B | |
| Enterprise value | 474.42B | 493.64B | 451.41B | 468.95B | 454B | |
| P/E ratio | 12.74 | 7.35 | -11.78 | -8.07 | -14.59 | |
| Price to sales ratio | 1.37 | 1.71 | 1.61 | 1.4 | 1.41 | |
| POCF ratio | 39.27 | 18.65 | 5.42 | -21.09 | 13.65 | |
| PFCF ratio | -161.29 | 398.8 | 6.53 | -11.34 | 22.19 | |
| P/B Ratio | 0.54 | 0.61 | 0.56 | 0.54 | 0.5 | |
| PTB ratio | 0.54 | 0.61 | 0.56 | 0.54 | 0.5 | |
| EV to sales | 3.19 | 3.63 | 3.52 | 3.34 | 3.57 | |
| Enterprise value over EBITDA | -1.79K | 16.37 | 55.86 | 89.71 | 56.02 | |
| EV to operating cash flow | 91.46 | 39.65 | 11.81 | -50.35 | 34.58 | |
| EV to free cash flow | -375.64 | 847.83 | 14.23 | -27.08 | 56.21 | |
| Earnings yield | 0.02 | 0.03 | -0.02 | -0.03 | -0.02 | |
| Free cash flow yield | -0.01 | 0 | 0.15 | -0.09 | 0.05 | |
| Debt to equity | 0.76 | 0.79 | 0.8 | 0.8 | 0.84 | |
| Debt to assets | 0.33 | 0.34 | 0.34 | 0.35 | 0.36 | |
| Net debt to EBITDA | -1.02K | 8.67 | 30.23 | 52.14 | 33.91 | |
| Current ratio | 1.04 | 1.31 | 1.27 | 1.17 | 1.18 | |
| Interest coverage | 4.7 | 8.9 | 0.76 | 1.5 | 1.32 | |
| Income quality | -2.26 | 1.2 | -7.4 | 1.28 | -3.07 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | |
| Research and developement to revenue | 0.04 | 0.05 | 0.05 | 0.06 | 0.05 | |
| Intangibles to total assets | 0.09 | 0.09 | 0.1 | 0.1 | 0.1 | |
| Capex to operating cash flow | -1.24 | -0.95 | -0.17 | 0.86 | -0.38 | |
| Capex to revenue | -0.04 | -0.09 | -0.05 | -0.06 | -0.04 | |
| Capex to depreciation | -1.21 | -2.17 | -1.15 | -1.42 | -0.93 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 13.34K | 18.86K | 13.92K | 16.19K | 11.45K | |
| ROIC | -0.02 | 0.03 | 0 | 0.01 | 0.01 | |
| Return on tangible assets | 0.01 | 0.01 | -0.01 | -0.01 | 0 | |
| Graham Net | -17.73K | -17.18K | -17.33K | -17.86K | -17.12K | |
| Working capital | 12.57B | 83.24B | 75.04B | 47.56B | 51.44B | |
| Tangible asset value | 296.98B | 299.12B | 289.02B | 281.51B | 278.68B | |
| Net current asset value | -136.53B | -135.08B | -141.8B | -145.27B | -137.94B | |
| Invested capital | 0.76 | 0.79 | 0.8 | 0.8 | 0.84 | |
| Average receivables | 216.33B | 226.37B | 215.26B | 214.42B | 211.52B | |
| Average payables | 119.49B | 115.42B | 112.49B | 113.1B | 103.94B | |
| Average inventory | 104.2B | 95.91B | 90.76B | 89.95B | 92.6B | |
| Days sales outstanding | 139.87 | 146.79 | 146.29 | 140.99 | 143.5 | |
| Days payables outstanding | 107.09 | 105.72 | 120.29 | 105.25 | 103.13 | |
| Days of inventory on hand | 87.11 | 89.93 | 92.12 | 86.98 | 99.34 | |
| Receivables turnover | 0.64 | 0.61 | 0.62 | 0.64 | 0.63 | |
| Payables turnover | 0.84 | 0.85 | 0.75 | 0.86 | 0.87 | |
| Inventory turnover | 1.03 | 1 | 0.98 | 1.03 | 0.91 | |
| ROE | 0.01 | 0.02 | -0.01 | -0.02 | -0.01 | |
| Capex per share | -468.64 | -861.2 | -473.17 | -581.76 | -366.74 |
002390.KS Frequently Asked Questions
What is HANDOK Inc. stock symbol ?
HANDOK Inc. is a KR stock and trading under the symbol 002390.KS
What is HANDOK Inc. stock quote today ?
HANDOK Inc. stock price is $12810 today.
Is HANDOK Inc. stock public?
Yes, HANDOK Inc. is a publicly traded company.
Company Profile
- Volume Average 19.98K
- Market Capitalization 178.51B
- Employee 911
- CEO Mr. Young-Jin Kim M.B.A.
- Headquarters Seoul,KR
- IPO Date 2000-01-04
-
Website
https://www.handok.co.kr 
Handok Inc. operates as an integrated pharmaceutical company. The company provides ETC and OTC drugs, medical devices, and in-vitro diagnostics instruments and devices. It focuses on various therapeutic areas, such as oncology, diabetes and metabolic disorders, CNS orphan diseases, eye disorders, and other disease areas. The company also offers healthcare products comprising food supplements under the NatureSet and Culturelle brands; food and beverages; and medical nutrition products. Handok Inc. has a strategic collaboration agreement with AUM Biosciences Pte. Ltd. and CMG Pharmaceutical Co. Ltd. for the development, manufacturing, and commercialization of CHC2014, a pan-TRK inhibitor for cancer treatment. The company was formerly known as Handok Pharmaceuticals Co., Ltd and changed its name to Handok Inc. in July 2013. Handok Inc. was founded in 1954 and is based in Seoul, South Korea.
